Clinical trial · Observational
Mutational Landscape in Hepatocellular Carcinoma
Translating Molecular Classifications and Genetic Alterations of Hepatocellular Carcinoma in Clinical Care (MUTHEC Project)
NCT03071458CI-TRIAL-00098731MUTHECcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The MUTHEC project aims to describe the mutational and transcriptomic landscape of HCC treated by curative treatments (resection, radio frequency ablation, transplantation) as well as advanced HCC together with the analysis of circulating tumor DNA.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cirrhosis | — | UNRESOLVED | — |
| HepatoCellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Patients with HCC
- description
- The cohort is composed of patients with HCC with available tumor and non tumor samples collected retrospectively. These patients have HCC of different stages (localized and advanced stages) It is an observational retrospective study.
Primary outcomes (1)
- measure
- Genetic and transcriptomic landscape
- timeFrame
- Up to 3 years
- description
- Identification of the main genetic driver and transcriptomic subgroups among a large panel of HCC
Secondary outcomes (3)
- measure
- Translation in immunohistochemical markers
- timeFrame
- Up to 3 years
- description
- The investigators aim to translate the major genetic drivers and oncogenic pathway dysregulated in HCC using immunohistochemistry. The investigators will test surrogate markers of the main genetic alterations and activation of oncogenic pathway using immunohistochemistry in HCC extensively reviewed by expert pathologists.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Written consent of the patient according to the French Law: the French Liver Biobanks network - AFAQ NF S96-900 and Hepatobio bank * Histologically proven hepatocellular carcinoma * Available frozen samples * HCC assessible to a curative treatment (Treated by resection, liver transplantation, radio frequency ablation) or advanced HCC with available biopsy Exclusion Criteria: * Less than 18 years old * Pregnancy at the date of the sample * Parafinn embedded tissue only available
References
Publications (1)
- RESULTBlaise L, Ziol M, Campani C, Ganne-Carrie N, Nahon P, Nkontchou G, Zucman-Rossi J, Del Pozo L, Barget N, Boros C, Desjonqueres E, Demory A, Grando V, Pescatori L, Seror O, Sutter O, Nault JC. Utility of tumor and non-tumor biopsies during percutaneous radiofrequency ablation for hepatocellular carcinoma. JHEP Rep. 2025 Apr 22;7(9):101430. doi: 10.1016/j.jhepr.2025.101430. eCollection 2025 Sep. PMID 40823168